Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.9M Buy
193,541
+853
+0.4% +$99.8K 1.31% 21
2026
Q1
$23.2M Buy
192,688
+57,869
+43% +$6.68M 1.62% 17
2025
Q4
$14.2M Buy
134,819
+691
+0.5% +$64.9K 0.9% 23
2025
Q3
$11.3M Buy
134,128
+46,410
+53% +$3.82M 0.74% 30
2025
Q2
$6.94M Buy
87,718
+2,410
+3% +$192K 0.5% 42
2025
Q1
$7.65M Sell
85,308
-2,363
-3% -$221K 0.64% 41
2024
Q4
$8.72M Buy
+87,671
New +$9.04M 0.69% 33

Other funds holding MRK

Triglav Skladi's MRK Position: Q2 2026 in Review

Triglav Skladi increased its Merck (MRK) stake by 0.44% in Q2 2026, buying an estimated $99.8K and bringing the position to 193,541 shares worth $24.9M. The position accounts for 1.31% of the portfolio, ranked #21.

Triglav Skladi first reported a position in MRK in Q4 2024 and has held it in 7 quarters since. 3,833 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Triglav Skladi held 193,541 shares of Merck worth $24.9M as of Q2 2026.
  • Triglav Skladi bought 853 Merck shares in Q2 2026, an estimated $99.8K.
  • Merck made up 1.31% of Triglav Skladi's portfolio in Q2 2026, its #21 holding.
  • Triglav Skladi first reported a position in Merck in Q4 2024 and has held it in 7 quarters since.
  • 3,833 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Triglav Skladi's 13F filing for Q2 2026, filed 11 Aug 2026.